Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 121,474 matching trials from the live ClinicalTrials.gov search.

Filters: Completed Clear all

Conditions: Metastatic Ureter Carcinoma, Metastatic Urethral Carcinoma, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Ureter Cancer AJCC v7, Stage III Urethral Cancer AJCC v7, Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Ureter Urothelial Carcinoma, Urethral Urothelial Carcinoma
Interventions: Eribulin Mesylate, Gemcitabine Hydrochloride; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 17
States / cities: Duarte, California • Los Angeles, California • Pasadena, California + 12 more

Conditions: Oral Cavity Cancer, Oropharyngeal Cancer, Lymphedema, Fibrosis
Interventions: LEF measures, Technical measure; Other · Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Advanced Solid Tumours
Interventions: AZD0156, Olaparib, irinotecan, Fluorouracil, Folinic Acid; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Aurora, Colorado • New York, New York

Conditions: Cervical Arthrodesis
Interventions: Cervical arthrodesis with rhBMP-2; Procedure
Lead sponsor: Virginia Spine Institute; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: Reston, Virginia

Conditions: Analgesia, Obstetrical
Interventions: Tegaderm dressing + catheter support pad, Tegaderm dressing + Steri-strip dressing, Tegaderm dressing only; Device
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Healthy
Interventions: Sumatriptan Succinate Tablets 100 mg, Imitrex® Tablets 100 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Myelodysplastic Syndromes
Interventions: Azacitidine; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Heart Failure
Interventions: Motivational Interviewing tailored intervention; Behavioral
Lead sponsor: Ruth Masterson-Creber; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Primary Total Knee Arthroplasty
Interventions: Pregabalin 50mg, Pregabalin 100mg, Pregabalin 150mg, Placebo; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Fibrodysplasia Ossificans Progressiva (FOP)
Interventions: Non-Interventional; Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Mental Health
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: Not listed
Enrollment: 228 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Infection
Interventions: Multivirus Specific T cells; Biological
Lead sponsor: AlloVir; Industry
Eligibility: Not listed
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Major Depressive Disorder
Interventions: AV-101, Placebo; Drug
Lead sponsor: VistaGen Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 22
States / cities: Garden Grove, California • Los Angeles, California • National City, California + 18 more

Conditions: Healthy Volunteers
Interventions: Genvoya Oral dose, Genvoya Crushed Dose; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatitis C
Interventions: Sofosbuvir, Placebo, PEG, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: San Francisco, California • Gainesville, Florida • Orlando, Florida + 3 more

Conditions: Hypercholesterolemia
Interventions: Ezetimibe 10 mg, Ezetimibe 5 mg; Drug
Lead sponsor: Bronx VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Older Persons Interested in Improving Their Brain Health
Interventions: Treatment as Usual, Cogtrastim Model; Behavioral
Lead sponsor: Nova Southeastern University; Other
Eligibility: 50 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Healthy
Interventions: APD791; Drug
Lead sponsor: Arena Pharmaceuticals; Industry
Eligibility: 19 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Osteoarthritis
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 40 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: To Determine Bioequivalence Under Fed Conditions
Interventions: Lisinopril; Drug
Lead sponsor: Par Pharmaceutical, Inc.; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Oral Complications of Radiation Therapy, Stage I Laryngeal Cancer, Stage II Laryngeal Cancer
Interventions: laser therapy, questionnaire administration; Procedure · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Not listed
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Diabetes Mellitus, Cardiovascular Disease
Interventions: Low support, Medium support, High support, Comparison; Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 75 Years
Enrollment: 166 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Depressive Disorder
Interventions: SSR149415; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Overweight, Obesity
Interventions: 500 mL/day of a beverage providing approximately 625 mg catechins, Control beverage matched for energy and caffeine content; Dietary Supplement · Other
Lead sponsor: Provident Clinical Research; Other
Eligibility: 21 Years to 65 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: St. Petersburg, Florida • Bloomington, Indiana

Search by objective public record fields.

Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery

Establishing Lymphedema and Fibrosis Measures in Oral Cancer Patients

Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer

rhBMP-2 in Cervical Arthrodesis

Intrapartum Epidural Catheter Displacement: Dressing Methods

Fasting Study of Sumatriptan Succinate Tablets 100 mg to Imitrex® Tablets 100 mg

A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes

Motivational Interviewing Tailored Intervention for Patients With Heart Failure (MITI-HF)

Effects of Pregabalin on Pain After Total Knee Arthroplasty

A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)

Duration and Direct Cost of Behavioral Health Concerns in Pediatric Primary Care

Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant

AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression

Analysis of Crushed and Whole Tablet Genvoya

Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients

Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)

A Comparison of Two Approaches to Developing Brain Health Programs

A Multiple-Dose Study to Assess the Safety, Tolerability, and Steady State Pharmacokinetics of APD791 in Healthy Volunteers

Epidemiology of Osteoarthritis (OA) Pain

A Comparative Bioavailability Study of Lisinopril Tablets, 40 mg - Effect of Food Study

Pulsed Dye Laser in Treating Patients With Post Radiation Dysphonia

SPREAD-NET: PRactices Enabling Adapting and Disseminating in the Safety NET

An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder

Efficacy of a Tea Catechin Sports Drink for Enhancing Exercise-Induced Fat Loss